Enhertu's Benes Conf. for HER2+ MBC; Could Help Early Stages
Enhertu's Benefits Confirmed for Metastatic, HER2-Positive Breast Cancer; Could Help Treat Early-Stage Disease
Dec 14, 2022
Updated results from the DESTINY-Breast02 and DESTINY-Breast03 studies confirmed the benefits of Enhertu for previously treated metastatic, HER2-positive breast cancer, and results from the TALENT trial suggest that the medicine may offer benefits for early-stage hormone receptor-positive, HER2-low breast cancer when given before surgery. Read more...